Observational studyEuropean journal of nuclear medicine and molecular imaging2024
Early response monitoring during [
Observational study in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Prognostic value of interim post-treatment SPECT/CT following lutetium-177 (177Lu)-PSMA therapy in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Investigating the significance of SPECT/CT-SUV for monitoringBMC medical imaging · 2025Pooled it
- Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Recurrent pulmonary lymphangitis carcinomatosis detected onEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617.European journal of nuclear medicine and molecular imaging · 2026Article
- The role of multimodality imaging in selection, response assessment, and follow-up of patients receivingInsights into imaging · 2026Article
- Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.Frontiers in oncology · 2025Review
- SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer ReceivingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Early treatment response assessment with [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Impact of Posttreatment SPECT/CT on Patient Management DuringJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [European journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess early tumor response with quantitated SPECT/CT and to correlate it with clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with
methodsSingle-center, observational study, part of the prospective Swiss national cancer registry study investigating the safety and efficacy of [
resultsBetween 07/2020 and 04/2022, 111 patients were screened and 73 finally included in the data analysis. The median follow-up was 8.9 months (range 1.4-26.6 months). Stable or decreased TTV at cycle 2 was associated with longer OS (hazard ratio (HR) 0.28, 95% confidence interval (CI) 0.09-0.86, p < 0.01). Similar, stable, or decreased PSA was associated with longer OS (HR 0.21; CI 0.07-0.62, p < 0.01) and PSA-PFS (HR 0.34; 95% CI 0.16-0.72, p < 0.01). Combining TTV and PSA will result in an augmented prognostic value for OS (HR 0.09; CI 0.01-0.63; p < 0.01) and for PSA-PFS (HR 0.11; CI 0.02-0.68; p < 0.01). A reduction of SUVmax or SUVmean was not prognostically relevant, neither for OS (p 0.88 and 0.7) nor for PSA-PFS (p 0.73 and 0.62, respectively).
conclusionSix weeks after initiating [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.